scholarly journals Increased systemic sST2 in patients with end stage renal disease contributes to milder liver damage during HCV infection

2020 ◽  
Vol 14 (05) ◽  
pp. 519-526
Author(s):  
Ruzica Lukic ◽  
Maja Cupic ◽  
Nevena Gajovic ◽  
Milena Jurisevic ◽  
Zeljko Mijailovic ◽  
...  
Keyword(s):  
Liver Disease ◽  
Hepatitis C ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hcv Infection ◽  
Hepatitis C Infection ◽  
Healthy Control ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Introduction: Hepatitis C Virus (HCV) is the leading cause of chronic liver disease and is a serious global health problem. Hepatitis C infection is highly prevalent in patients with end stage renal disease (ESRD), due to frequent exposure to blood and blood products, nosocomial transmission of HCV, and prolong hemodialysis duration. The aim of the study was to evaluate the influence of IL-33/ST2 signaling pathway on severity of the liver disease in ESRD HCV+ patients. Methodology: Blood samples from patients with end stage renal disease (ESRD) and hepatitis C infection (HCV), 20 patients with HCV infection, 20 patients with ESRD and 20 healthy control donor patients were taken for the examination of biochemical parameters, for the determination of the serum cytokine concentration, and for the molecular diagnostics of HCV. Results: Systemic sST2 positively correlated with serum level of urea and creatinine, respectively. Serum sST2 was significantly increased in ESRD HCV+ patients in comparison to HCV+ group. sST2/IL-1, sST2/IL-4 and sST2/IL-23 ratios were significantly increased in serum of ESRD HCV+ patients in comparison to HCV+ patients. Significantly higher systemic level of sST2 and sST2/IL-1 and sST2/IL-4 ratios were measured in ESRD patients compared to non-ESRD patients. Conclusion: These results suggested that elevated level sST2, as the consequence of renal failure, causes less destruction of liver in HCV infection.

Hepatitis C infection in end stage renal disease children

1998 ◽  
Vol 114 ◽  
pp. A1304
Author(s):  
Z. Molle ◽  
S. Rabinowitz ◽  
N. Baqi ◽  
S. Piecuch
Keyword(s):  
Hepatitis C ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hepatitis C Infection ◽  
Stage Renal Disease ◽  
End Stage

Hepatitis C infection and the patient with end-stage renal disease

Hepatology ◽  
2002 ◽  
Vol 36 (1) ◽  
pp. 3-10 ◽  
Author(s):  
Fabrizio Fabrizi ◽  
F. Fred Poordad ◽  
Paul Martin
Keyword(s):  
Hepatitis C ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hepatitis C Infection ◽  
Stage Renal Disease ◽  
End Stage

Hepatitis C infection in children and adolescents with end-stage renal disease

2002 ◽  
Vol 17 (6) ◽  
pp. 444-449 ◽  
Author(s):  
Zarela L. Molle ◽  
Noosha Baqi ◽  
David Gretch ◽  
Guillermo Hidalgo ◽  
Amir Tejani ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Renal Disease ◽  
Children And Adolescents ◽  
End Stage Renal Disease ◽  
Hepatitis C Infection ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Upper gastrointestinal bleeding in patients with end stage renal disease: causes, characteristics and factors associated with need for endoscopic therapeutic intervention

2017 ◽  
Vol 5 (2) ◽  
pp. 106-111 ◽  
Author(s):  
Syed Mudassir Laeeq ◽  
Abbas Ali Tasneem ◽  
Farina M. Hanif ◽  
Nasir Hassan Luck ◽  
Rajesh Mandhwani ◽  
...  
Keyword(s):  
Liver Disease ◽  
Gastrointestinal Bleeding ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Upper Gastrointestinal Bleeding ◽  
Factors Associated ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients ◽  
Upper Gastrointestinal

Abstract Background and Objectives The risk of upper gastrointestinal bleeding (UGIB) is increased among the end-stage renal disease (ESRD) patients. The aim of the current study was to describe the causes and characteristics of UGIB in ESRD patients at our center and to assess the need for endoscopic therapeutic intervention (ETI) using Rockall (RS) and Glasgow Blatchford scores (GBS). Material and Methods All patients with ESRD and UGIB with age ≥14 years were included. Frequencies and percentages were computed for categorical variables. Chi square test or Fischer’s exact test was used for statistical analysis. Results A total of 59 subjects had a mean age of 47.25 ± 15 years.The most common endoscopic findings seen were erosions in 33 (55.9%) patients, followed by ulcers in 18 (30.3%) patients. ETI was required in 33 (55.9%) patients, which included adrenaline injection in 19 (32.3%), hemoclip in 9 (15.2%) and argon plasma coagulation in 5 (8.4%) patients. Factors associated with the need of ETI were identified as: a combined presentation of hematemesis and melena (P=0.033), ulcer (P=0.002) and associated chronic liver disease (P=0.015). Six (10.1%) patients died. Death was more common if ETI was not performed (P=0.018). Conclusion ETI was more commonly required in patients on maintenance hemodialysis with UGIB, who had presence of combined hematemesis and melena, ulcers and associated chronic liver disease. A Glasgow Blatchford score of >14 was helpful in assessing the need for ETI in these patients.

scholarly journals The outcome of Daclatasvir and low dose Sofosbuvir therapy in end-stage renal disease patients with hepatitis C virus infection

2020 ◽  
pp. 3-8
Author(s):  
M. Mostafi ◽  
M. Jabin ◽  
Z. Chowdhury ◽  
M.U. Khondoker ◽  
S.M. Ali ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Side Effects ◽  
End Stage Renal Disease ◽  
Low Dose ◽  
Hcv Infection ◽  
Full Dose ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Rapid progression of chronic kidney disease (CKD) is seen in patients with hepatitis C virus (HCV) infection compared with uninfected patients. Despite the high efficacy of direct-acting antivirals (DAAVs), their cost represents a limiting factor to their use in developing countries. Aim. This study aimed to evaluate the efficacy of low dose Sofosbuvir along with Daclatasvir in the management of HCV infection in end-stage renal disease (ESRD) patients. Methods. A total of 82 HCV positive patients on ESRD were included in this study. The patients were observed for six months without antiviral drugs. Patients who remained seropositive were divided into two groups. The first group included 26 (37%) patients who were treated with half-dose Sofosbuvir 200 mg and Daclatasvir 60 mg and the second group consisted of 44 (63%) patients who have been treated with full-dose Sofosbuvir 400 mg and Velpatasvir 100 mg irrespective of HCV infection genotype for 12 weeks also. Results. 12 (14%) patients became seronegative spontaneously. All patients (100%) of both groups achieved sustained virological response with undetectable HCV RNA in 12 weeks of the treatment. There were nonsignificant gastrointestinal side effects in the full dose Sofosbuvir group. All patients tolerated the DAAs well. No patient discontinued antiviral therapy due to side effects Conclusion. In this study, the spontaneous seroconversion of HCV was 14%. Low-dose Sofosbuvir along with Daclatasvir was safe and as effective as full-dose Sofosbuvir and Velpatasvir in the treatment of HCV in ESRD patients. Low-dose Sofosbuvir regimen can be recommended for HCV infection treatment in ESRD patients.

Sign in / Sign up

Export Citation Format

Share Document